{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:02:23Z","timestamp":1793397743051,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.revmed.2023.06.004","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T16:17:19Z","timestamp":1688487439000},"page":"546-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beh\u00e7et's disease uveitis"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-0459","authenticated-orcid":false,"given":"M.","family":"Joubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Domont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ghembaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lejoncour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-8043","authenticated-orcid":false,"given":"A.","family":"Mirouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Maalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6262-1740","authenticated-orcid":false,"given":"M.","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Touhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2023.06.004_bib0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13023-020-01620-4","article-title":"French recommendations for the management of Beh\u00e7et's disease","volume":"16","author":"Kone-Paut","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2023.06.004_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/1744666X.2016.1205486","article-title":"Behcet's disease: epidemiology, clinical manifestations, and diagnosis","volume":"13","author":"Davatchi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0010","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.24423","article-title":"Epidemiology and clinical characteristics of Beh\u00e7et's disease in the US: a population-based study","volume":"61","author":"Calamia","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.06.004_bib0015","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/bmj.304.6836.1199","article-title":"Beh\u00e7et's disease","volume":"304","author":"Wechsler","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2023.06.004_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12969-016-0070-z","article-title":"Beh\u00e7et's disease in children, an overview","volume":"14","author":"Kon\u00e9-Paut","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.revmed.2023.06.004_bib0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0030","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","article-title":"Epidemiology of Beh\u00e7et disease","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.revmed.2018.02.022","article-title":"Les manifestations oculaires de la maladie de Beh\u00e7et","volume":"39","author":"Desbois","year":"2018","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2023.06.004_bib0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et's Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0045","first-page":"175","article-title":"Relationship between age at onset and clinical characteristics of Beh\u00e7et's disease","volume":"27","author":"Ghembaza","year":"2018","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.revmed.2023.06.004_bib0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/09273948.2013.795228","article-title":"Differential diagnosis of beh\u00e7et uveitis","volume":"21","author":"Tugal-Tutkun","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0055","first-page":"529","article-title":"Ocular manifestations of Beh\u00e7et's disease","volume":"150","author":"Cassoux","year":"1999","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.revmed.2023.06.004_bib0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/IIO.0b013e318265d56a","article-title":"Imaging in the diagnosis and management of Beh\u00e7et disease","volume":"52","author":"Tugal-Tutkun","year":"2012","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.revmed.2023.06.004_bib0065","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/eye.2014.138","article-title":"Long-term efficacy of infliximab on background vascular leakage in patients with Beh\u00e7et's disease","volume":"28","author":"Keino","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.revmed.2023.06.004_bib0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","article-title":"Review for diagnostics of the year: multimodal imaging in Beh\u00e7et Uveitis","volume":"25","author":"Tugal-Tutkun","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0075","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1038\/s41598-019-45149-4","article-title":"Association between subfoveal choroidal thickness and leakage site on fluorescein angiography in Beh\u00e7et's uveitis","volume":"9","author":"Shirahama","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.revmed.2023.06.004_bib0080","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/IAE.0000000000001587","article-title":"Quantitative analysis of structural alterations in the choroid of patients with active Beh\u00e7et uveitis","volume":"38","author":"Onal","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.revmed.2023.06.004_bib0085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/09273948.2019.1612452","article-title":"Optical coherence tomography angiography findings in active and inactive ocular Beh\u00e7et disease","volume":"28","author":"Accorinti","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0090","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/09273948.2020.1736310","article-title":"An algorithm for the diagnosis of Beh\u00e7et disease uveitis in adults","volume":"29","author":"Tugal-Tutkun","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0095","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1080\/09273948.2017.1335756","article-title":"Intravitreal adalimumab for the control of breakthrough intraocular inflammation","volume":"26","author":"Kheir","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.62.3.8","article-title":"Parafoveal microvascular alterations in ocular and non-ocular Beh\u00e7et's disease evaluated with optical coherence tomography angiography","volume":"62","author":"Smid","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.revmed.2023.06.004_bib0105","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/s41433-020-01294-z","article-title":"Preclinical ocular features in patients with Beh\u00e7et's disease detected by optical coherence tomography angiography","volume":"35","author":"Karalezli","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.revmed.2023.06.004_bib0110","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/IAE.0000000000002177","article-title":"Optical coherence tomography angiography findings in patients with monocular Beh\u00e7et disease","volume":"39","author":"Raafat","year":"2019","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.revmed.2023.06.004_bib0115","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00417-008-0823-6","article-title":"Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Beh\u00e7et uveitis","volume":"246","author":"Tugal-Tutkun","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.revmed.2023.06.004_bib0125","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.06.004_bib0130","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Beh\u00e7et's syndrome: a systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.06.004_bib0135","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.06.004_bib0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","article-title":"Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: a multicenter study of 330 patients","volume":"238","author":"Maalouf","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","article-title":"Beh\u00e7et's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab","volume":"58","author":"Kaburaki","year":"2014","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0150","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ajo.2021.07.036","article-title":"Comment on \u201cClassification Criteria for Beh\u00e7et Disease Uveitis\u201d","volume":"235","author":"Tugal-tutkun","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0155","first-page":"1","article-title":"Fluorescein angiographic findings and Behcet's disease ocular attack score 24 (BOS24) as prognostic factors for visual outcome in patients with ocular Behcet's disease","volume":"7","author":"Keorochana","year":"2021","journal-title":"Int J Retina Vitrrous"},{"key":"10.1016\/j.revmed.2023.06.004_bib0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/25785826.2020.1800244","article-title":"Evaluation of disease activity in uveoretinitis associated with Beh\u00e7et's disease","volume":"44","author":"Keino","year":"2021","journal-title":"Immunol Med"},{"key":"10.1016\/j.revmed.2023.06.004_bib0195","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00417-008-0765-z","article-title":"Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit","volume":"246","author":"Manzano","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IAE.0b013e3181e378af","article-title":"Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema","volume":"31","author":"Bae","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.revmed.2023.06.004_bib0165","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0170","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","article-title":"Intravitreal infliximab for sight-threatening relapsing uveitis in Beh\u00e7et disease: a pilot study in 15 patients","volume":"154","author":"Markomichelakis","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0175","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","article-title":"Intravitreal infliximab in refractory uveitis in Behcet's disease: a safety and efficacy clinical study","volume":"36","author":"Hamza","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.revmed.2023.06.004_bib0180","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/IAE.0000000000003095","article-title":"Monthly intravitreal infliximab in Behcet's disease active posterior uveitis: a long-term safety study","volume":"41","author":"Refaat","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.revmed.2023.06.004_bib0185","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","article-title":"Intravitreal adalimumab for refractory uveitis-related macular edema","volume":"117","author":"Androudi","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.06.004_bib0190","first-page":"319","article-title":"Intravitreal adalimumab in active noninfectious uveitis: a pilot study","volume":"24","author":"Hamam","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0200","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00417-009-1065-y","article-title":"Evaluation of potential retinal toxicity of adalimumab (Humira)","volume":"247","author":"Tsilimbaris","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2023.06.004_bib0215","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2023.06.004_bib0220","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et's syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1016\/j.revmed.2023.06.004_bib0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et's syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0230","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","article-title":"Effectiveness of cyclosporin therapy for Beh\u00e7et's disease","volume":"28","author":"Nussenblatt","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.06.004_bib0235","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin-A therapy in severe uveitis of Beh\u00e7et's disease","volume":"76","author":"S\u00fcll\u00fc","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.revmed.2023.06.004_bib0240","doi-asserted-by":"crossref","first-page":"372S","DOI":"10.1016\/j.transproceed.2004.01.003","article-title":"Experience with cyclosporine in endogenous uveitis posterior","volume":"36","author":"Hesselink","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.revmed.2023.06.004_bib0245","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/1756-185X.12139","article-title":"Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15\u00a0years","volume":"16","author":"Davatchi","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.revmed.2023.06.004_bib0250","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0255","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0260","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14728214.2020.1847271","article-title":"Beh\u00e7et's disease uveitis: is there a need for new emerging drugs?","volume":"25","author":"Tugal-Tutkun","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.revmed.2023.06.004_bib0265","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","article-title":"Long-term efficacy of interferon in severe uveitis associated with Beh\u00e7et disease","volume":"25","author":"Diwo","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.revmed.2023.06.004_bib0270","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et's disease with sight threatening posterior or panuveitis","volume":"87","author":"K\u00f6tter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0275","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","article-title":"Pegylated interferon-\u03b1-2b reduces corticosteroid requirement in patients with Beh\u00e7et's disease with upregulation of circulating regulatory T cells and reduction of Th17","volume":"74","author":"Lightman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.06.004_bib0280","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09273948.2017.1332768","article-title":"Long-term efficacy of pegylated interferon alpha-2b in Beh\u00e7et's uveitis: a small case series","volume":"27","author":"Celiker","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0285","first-page":"599","article-title":"Potential of pegylated interferon alpha-2a in Beh\u00e7et uveitis: a report of five cases","volume":"24","author":"Bielefeld","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0290","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Beh\u00e7et disease: review of the literature","volume":"33","author":"K\u00f6tter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.06.004_bib0295","doi-asserted-by":"crossref","first-page":"102481","DOI":"10.1016\/j.jaut.2020.102481","article-title":"Comparison of conventional immunosuppressive drugs versus anti-TNF-\u03b1 agents in non-infectious non-anterior uveitis","volume":"113","author":"Leclercq","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2023.06.004_bib0300","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-tumor necrosis factor \u03b1 versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.06.004_bib0305","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2023.06.004_bib0310","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2023.06.004_bib0315","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fphar.2020.00941","article-title":"Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets\u2019 disease-associated uveitis: a systematic review and meta-analysis","volume":"11","author":"Hu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2023.06.004_bib0325","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et's disease: National Multicenter Study of 177 cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0330","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-year retention rate of infliximab in patients with Beh\u00e7et's disease-related uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0335","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1080\/09273948.2020.1749857","article-title":"Escalation to weekly adalimumab for the treatment of ocular inflammation","volume":"29","author":"Liberman","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0340","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000336187","article-title":"Anti-tumor necrosis factor-\u03b1 agents in noninfectious uveitis","volume":"51","author":"Gueudry","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0345","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0350","first-page":"320","article-title":"Golimumab treatment for complicated uveitis","volume":"31","author":"Miserocchi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0355","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ddr.21285","article-title":"Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancy","volume":"76","author":"Pereira","year":"2015","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.revmed.2023.06.004_bib0360","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/imt.15.4","article-title":"Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?","volume":"7","author":"Atzeni","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.revmed.2023.06.004_bib0365","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.06.004_bib0370","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.06.004_bib0375","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0380","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the treatment of Beh\u00e7et uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy","volume":"26","author":"Eser Ozturk","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0385","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et's disease: multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.revmed.2023.06.004_bib0390","first-page":"1575","article-title":"IL-6 blockade for Beh\u00e7et's disease: review on 31 anti-TNF naive and 45 anti-TNF experienced patients","volume":"40","author":"Arida","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0395","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of gevokizumab in patients with Beh\u00e7et's disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0400","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study","volume":"71","author":"G\u00fcl","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.06.004_bib0405","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet's disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0410","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et's disease: a multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0415","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00296-017-3775-5","article-title":"Biological therapies for the treatment of Beh\u00e7et's disease-related uveitis beyond TNF-alpha blockade: a narrative review","volume":"38","author":"Sota","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2023.06.004_bib0420","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.06.004_bib0425","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.revmed.2023.06.004_bib0430","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.06.004_bib0435","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","article-title":"Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et's phenotype: a multicentre study","volume":"79","author":"Fagni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.06.004_bib0440","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting interleukin-23 in the treatment of noninfectious uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.06.004_bib0445","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.revmed.2023.06.004_bib0450","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.06.004_bib0455","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as remission induction therapy in Beh\u00e7et disease: a 20-year experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.06.004_bib0460","doi-asserted-by":"crossref","first-page":"rkx004","DOI":"10.1093\/rap\/rkx004","article-title":"Short-term efficacy of abatacept in the treatment of refractory ocular and cutaneous Beh\u00e7et's disease","volume":"1","author":"Maciel","year":"2017","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.revmed.2023.06.004_bib0465","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.06.004_bib0470","first-page":"38","article-title":"Daclizumab withdrawn from the market, worldwide","volume":"56","year":"2018","journal-title":"Drug Ther Bull"},{"issue":"11","key":"10.1016\/j.revmed.2023.06.004_bib0475","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.06.004_bib0480","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.revmed.2023.06.004_bib0485","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"issue":"16","key":"10.1016\/j.revmed.2023.06.004_bib0490","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et's syndrome\u00a0\u2013\u00a0a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2023.06.004_bib0495","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et's syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2023.06.004_bib0500","doi-asserted-by":"crossref","first-page":"626792","DOI":"10.3389\/fimmu.2020.626792","article-title":"Apremilast in refractory Beh\u00e7et's syndrome: a multicenter observational study","volume":"11","author":"Vieira","year":"2020","journal-title":"Front Immunol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323006677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323006677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:47:04Z","timestamp":1759337224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866323006677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0248866323006677"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.06.004","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beh\u00e7et's disease uveitis","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}